VirTech Bio is pioneering the development of OxyBridge™, an advanced human-derived hemoglobin-based oxygen carrier (HBOC) designed to address critical medical needs in situations where traditional blood transfusions are not feasible. This innovative platform aims to provide immediate oxygenation for trauma patients suffering from hemorrhagic shock and to enhance the viability of donor organs prior to transplantation. OxyBridge™ is characterized by its unique ultra-polymer design, which mitigates the risk of blood pressure increases associated with previous HBOC generations. The product is engineered for long shelf life without refrigeration, making it suitable for stockpiling in emergency situations, particularly for military applications. 

In addition to its in vivo applications for trauma care, OxyBridge™ is also being developed for ex vivo use in organ perfusion devices, which are crucial for maintaining organ viability before transplantation. The formulation is designed to closely mimic the viscosity and osmotic properties of blood, thereby preventing fluid shifts and protecting blood vessels. VirTech Bio has established a partnership with FUJIFILM Diosynth Biotechnologies for the scalable manufacturing of OxyBridge™, ensuring a cost-effective production process. With anticipated market entry in early 2025, the company is positioned to lead advancements in hemoglobin oxygen carrier solutions, supported by significant funding from the U.S. Department of Defense and a strong scientific advisory team.

United States

VirTech Bio is an early-stage biotech company based in Natick, MA. The Company has developed a proprietary HBOC solution for in vivo applications like severe blood loss and such ex vivo applications as supporting organs prior to transplant. Our team of scientists, engineers and industry veterans are committed to delivering a universal HBOC solution to fulfill significant unmet medical needs and save lives when minutes matter. It’s About Time.

VirTech Bio

Company Details